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Abstract
Background: Only a few previous studies have focused on the long-term prognosis of the patients
with infective endocarditis (IE). Our purpose was to delineate factors potentially associated with
the long-term outcome of IE, recurrences of IE and requirement for late valve surgery.
Methods: A total of 326 episodes of IE in 303 patients were treated during 1980–2004 in the
Turku University Hospital. We evaluated the long-term outcome and requirement for late valve
surgery for 243 of these episodes in 226 patients who survived longer than 1 year after the initial
admission. Factors associated with recurrences were analysed both for the 1-year survivors and
for all 303 patients.
Results: The mean (SD) follow-up time for the 1-year survivors was 11.5 (7.3) years (range 25
days to 25.5 years). The overall survival was 95%, 82%, 66%, 51% and 45% at 2, 5, 10, 15 and 20
years. In age and sex adjusted multivariate analyses, significant predictors for long-term overall
mortality were heart failure within 3 months of admission (HR 1.97, 95% CI 1.27 to 3.06; p = 0.003)
and collagen disease (HR 2.54, 95% CI 1.25 to 5.19; p = 0.010) or alcohol abuse (HR 2.39, 95% CI
1.30 to 4.40; p = 0.005) as underlying conditions, while early surgery was significantly associated
with lower overall mortality rates (HR 0.31, 95% CI 0.17 to 0.58; p < 0.001). Heart failure was also
significantly associated with the long-term cardiac mortality (p = 0.032). Of all 303 patients, 20 had
more than 1 disease episode. Chronic dialysis (p = 0.002), intravenous drug use (p = 0.002) and
diabetes (p = 0.015) were significant risk factors for recurrent episodes of IE, but when analysed
separately for the 1-year survivors, only chronic dialysis remained significant (p = 0.017).
Recurrences and late valve surgery did not confer a poor prognosis.
Conclusion: Heart failure during the index episode of IE was the complication, which significantly
predicted a poor long-term outcome. Patients who underwent surgery during the initial
hospitalisation for IE faired significantly better than those who did not.
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Background
The short-term outcome of infective endocarditis (IE) has
been examined in several previous studies from the 1990's
and 2000's [1-4], whereas only a small number of studies
have addressed the long-term prognosis of the patients
with IE. Moreover, most of the studies focusing on the
long-term prognosis have involved only certain sub-
groups of patients, e.g., those with late prosthetic valve IE
[5], IE with perivalvular abscess [6], surgically treated IE
associated with intravenous drug use (IVDU) [7], or
native valve IE in non-addicts [8], as well as of those
undergone surgery for defined indications, e.g. aortic
valve IE [9], mitral valve IE [10], or native or prosthetic
valve IE [11]. Instead, the long-term outcome of IE in large
series of unselected patients with IE has been the focus of
rather few studies [12-15].
We have previously analysed the short-term and 1-year
clinical outcome of 303 patients with 326 episodes of IE
treated in our hospital during the years 1980–2004 [16].
In the present study, we set out to analyse the long-term
clinical outcome of 243 of these episodes in 226 patients
who survived longer than 1 year after the initial admission
for IE. Our purpose was to delineate the clinical character-
istics of the patients during the index hospitalisation for
IE, which might be predictive of the long-term outcome of
IE. One important issue involved the impact of early sur-
gery on the long-term survival of the patients. We also
evaluated risk factors potentially associated with the
development of recurrences of IE and the requirement for
late valve surgery.
Methods
Between 1980 and 2004, 303 patients with 326 episodes
of IE were treated in the Turku University Hospital, Turku,
Finland. We evaluated the long-term outcome of 226 of
these patients who survived longer than 1 year after the
initial admission. The hospital is a 1000-bed teaching
facility with a cardiothoracic surgical department, serving
as a tertiary referral centre for the southwestern part of the
country, and as a primary care facility for infectious dis-
eases for a region of about 200.000 inhabitants.
For each patient, data on age, sex, underlying diseases,
causative agents of IE, affected valves, predisposing car-
diac conditions and echocardiographic findings, as well as
the development of complications and the need for valve
surgery were collected by us for our previous study focus-
ing on the changes of the clinical characteristics of IE dur-
ing the 25-year study period [19]. In addition, serum C-
reactive protein (CRP) values, erythrocyte sedimentation
rates (ESR) and white blood cell (WBC) counts on admis-
sion were registered previously [16,20], as were the results
of the polymerase chain reaction analyses from the
removed valve tissue for those patients who underwent
surgery during 1994–2005 [21]. In the present study,
these data were used to analyse the association between
various patient and disease characteristics and the long-
term outcome of the patients after an episode of IE. The
survival and causes of death were assessed based on data
obtained from the National Population Registry, in which
all deaths and causes of deaths of the Finnish residents are
registered. The patients were also analysed for factors asso-
ciated with recurrent episodes of IE and with requirement
for late valve surgery. Data regarding the recurrences and
late valve surgery were obtained from the hospital records
of the patients.
The follow-up period for the outcome was from the
admission to death, or if alive, up to February 2006.
Definitions
Long-term outcome was defined as the outcome > 1 year
after the admission for the index episode of IE. Early sur-
gery was defined as surgery during the index hospitalisa-
tion, and late surgery was defined as surgery > 1 year after
the initial admission. A recurrence was defined as a new
episode of IE caused by a different microorganism or by a
microorganism of the same genus or species of the previ-
ous episode of IE after a period of more than 6 months. A
relapse was defined as a new episode of IE caused by a
microorganism of the same genus and species within 6
months after discharge.
The study was approved by the Institutional Committee
on human research.
Statistical analysis
Four different end-points were analysed in the study:
long-term overall mortality, long-term cardiac mortality,
late valve surgery, and recurrent IE. The associations
between the clinical characteristics and end-points were
studied separately using survival analysis. The cumulative
percentages for survival during different time periods were
estimated using the Kaplan-Meier technique. Differences
in cumulative percentages between groups were tested
using log-rank test. Data regarding the long-term overall
outcome, cardiac mortality, and late valve surgery were
analysed for the 1-years survivors, and data regarding the
repeated episodes of IE both for the 1-year survivors and
for all 303 patients.
Early surgery, late surgery and recurrent IE were analysed
as time-dependent covariates applying Cox's regression
models. Differences between groups were quantified by
hazard ratios and ninety-five percent confidence intervals.
Multivariate analyses of end-points were carried out using
the Cox regression model with early surgery as a time-
dependent covariate. Stepwise method was used forBMC Infectious Diseases 2008, 8:49 http://www.biomedcentral.com/1471-2334/8/49
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model selection. The results of multivariate analysis were
adjusted for age and sex and differences between groups
were quantified by hazard ratios and ninety-five percent
confidence intervals. Except for the laboratory parameters
and indications for surgery, all of the clinical characteris-
tics presented in Table 1 were included in multivariate
analyses.
P-values less than 0.05 were considered as statistically sig-
nificant. Statistical computations were carried out using
SAS® release 9.1/2005.
Results
The mean (SD) follow-up time for the 303 patients with
326 episodes of IE treated between 1980–2004 was 12.2
(7.4) years (range 1.0 to 25.5 years). The median survival
was 5.0 years for all patients, and the range of survival for
those who died during the follow-up was 4 days to 23
years. The overall survival for all 303 patients was 75%,
72%, 62%, 49%, 38% and 34 % at 1, 2, 5, 10, 15, and 20
years. We included in this study the 226 patients, who sur-
vived longer than 1 year after the initial admission for IE.
These patients had altogether 243 episodes of IE, of which
155 were designated as definite IE and the rest as possible
IE by the Duke diagnostic criteria [17]. A detailed diagnos-
tic classification has been previously published by us for
142 of these episodes [18].
There were 174 episodes in men and 69 episodes in
women. The mean age (SD) of the patients was 52.4
(17.1) years (range 18 to 87 years). The mean (SD) fol-
low-up time for the l-year survivors was 11.5 (7.3) years
(range 25 days to 25.5 years), and the 25% percentile of
the follow-up time was 4.8 years and the 75% percentile
of the follow-up time was 17.8 years. The median survival
was 7.1 years, and the range of survival for those who died
during the follow-up was 4 days to 22.3 years. Of these
patients, 67 underwent in-hospital valve surgery and 72
were treated both surgically and conservatively within 3
months of the admission. The proportions of various clin-
ical characteristics (e.g. causative agents of IE, affected
valves, predisposing cardiac conditions, development of
complications) are presented in Tables 1 and 2. A total of
94 patients died during the follow-up. The causes of death
were: recurrent IE (n = 1), sequelae of IE (n = 27), coro-
nary heart disease (n = 18), malignancy (n = 16), infection
other than IE (n = 14), stroke (n = 6), other or unknown
cause (n = 12). Of the 27 patients who died of sequelae of
IE, the cause of death was established to be heart failure in
18 patients and sudden death due to arrhythmia in 9
patients.
Long-term overall outcome
Among the 1-year survivors, the long-term overall survival
was 95%, 82%, 66%, 51%, and 45% at 2, 5, 10, 15, and
20 years (Figure 1). The association between the survival
and various clinical characteristics during the initial epi-
sode of IE is presented in Table 1. In univariate analysis,
an age ≥ 65 years when contracting the disease was signif-
icantly associated with higher mortality, as was malig-
nancy, collagen disease, chronic dialysis, or alcohol abuse
as underlying conditions. Mortality was significantly
higher for the patients who developed heart failure within
3 months of the initial admission than for those with no
heart failure (Figure 2a). Significant differences in mortal-
ity were observed between the patients with different pre-
disposing cardiac conditions, the mortality being highest
for the patients with congenital heart disease and lowest
for the patients with bicuspid aortic valve. Mortality was
significantly lower for the patients with IVDU than for
those with no IVDU. The long-term survival was signifi-
cantly better for the patients who underwent early (in-
hospital) surgery than for those who did not (Figure 2b).
Survival was significantly better for the patients who were
treated both surgically and conservatively within 3
months than for those who were treated only conserva-
tively. There were significant differences in survival
between the patients who underwent surgery on different
indications, the survival being lowest for those operated
on for heart failure.
Data on the serum CRP value, ESR, WBC count, and
serum creatinine value on admission was available in 205,
149, 217, and 218 episodes of endocarditis, respectively.
Higher survival rates were significantly associated with
ESR value < 50 mm/h, or serum creatinine value < 100
μmol/l on admission.
In age and sex adjusted multivariate analysis, significant
predictors for mortality were heart failure within 3
months of admission (HR 1.97, 95% CI 1.27 to 3.06; p =
0.003) and collagen disease (HR 2.54, 95% CI 1.25 to
5.19; p = 0.010) or alcohol abuse (HR 2.39, 95% CI 1.30
to 4.40; p = 0.005) as underlying conditions. Early surgery
was significantly associated with lower overall mortality
rates (HR 0.31, 95% CI 0.17 to 0.58; p < 0.001). Also
when recurrent episodes of IE were excluded from the
analyses, heart failure (HR 1.73, 95% CI 1.10 to 2.72; p =
0.018), collagen disease (HR 2.67, 95% CI 1.30 to 5.49; p
= 0.008), and alcohol abuse (HR 2.80, 95% CI 1.51 to
5.19; p = 0.001) remained significant risk factors for mor-
tality, and early surgery was significantly associated with
lower overall mortality rates (HR 0.32, 95% CI 0.17 to
0.59; p < 0.001).
Long-term cardiac mortality
Among the 1-year survivors, the long-term cardiac mortal-
ity was 3%, 10%, 16%, 25%, and 29% at 2, 5, 10, 15, and
20 years (Figure 1). In univariate analysis, cardiac mortal-
ity was significantly associated with an age ≥ 65 yearsBMC Infectious Diseases 2008, 8:49 http://www.biomedcentral.com/1471-2334/8/49
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Table 1: Association between characteristics of infective endocarditis (IE) and survival (global and in different subgroups) at 2, 5, 10, 
15, and 20 years after the admission in 243 episodes of IE in 226 patients who survived over 1 year after the initial episode of IE
Number of IE episodes in patients 
surviving 1 year
Survival (%) at different points of follow-up p value
2 years 5 years 10 years 15 years 20 years
Global survival 2 4 3 9 5 8 26 65 14 5
Gender
Male 174 97 83 68 50 45 0.567
Female 69 91 80 59 51 46
Age
18–64 years 172 99 90 76 60 54 < 0.001
≥ 6 5  y e a r s 7 1 8 7 6 53 82 52 5
Affected valves
Aortic 85 95 85 63 52 46 0.171*
Mitral valve 77 95 80 58 40 40
Tricuspid valve 12 100 100 100 NA† NA
Two native valves 17 100 100 91 76 76
Prosthetic valve(s) 52 94 74 67 52 43
Causative agents of IE
Staphylococcus aureus 53 98 86 77 57 57 0.183*
Coagulase-negative staphylococci 22 86 58 41 41 41
Viridans streptococci 50 96 91 77 56 50
Enterococcus faecalis 18 83 83 67 28 28
Streptococcus pneumoniae 5 1 0 0 1 0 05 35 35 3
O t h e r 2 2 9 5 9 16 66 03 0
Negative 73 99 78 61 46 46
Predisposing cardiac condition
Acquired valvular disea s e 4 9 9 0 7 05 34 13 6 0 . 0 1 9
Prosthetic valves 55 95 75 66 52 43
Bicuspid aortic valve 26 100 100 94 81 81
Mitral valve prolapse 30 97 93 74 62 62
Congenital heart disease 8 100 100 33 33 NA
No underlying cardiac condition 75 97 83 63 39 39
Echocardiogarphic findings
Major criteria
Yes 158 96 85 68 53 49 0.089
No 85 95 78 61 46 39
Vegetation 0.162
Yes 139 95 85 68 52 49
N o 1 0 4 9 6 8 06 24 94 1
Underlying conditions
Diabetes
Y e s 2 1 9 5 9 57 75 82 9 0 . 3 0 7
N o 2 2 2 9 5 8 16 44 94 5
Dialysis
Yes 5 60 40 NA NA NA 0.018
N o 2 3 8 9 6 8 36 65 14 6
Collagen disease
Y e s 1 4 9 3 6 82 42 42 4 0 . 0 2 6
N o 2 2 9 9 6 8 36 85 24 6
Malignancy
Yes 11 82 62 31 NA NA 0.004
N o 2 3 2 9 6 8 36 75 34 7
Intravenous drug use
Y e s 1 9 1 0 0 1 0 0N AN AN A 0 . 0 4 9
N o 2 2 4 9 5 8 16 45 04 4
Alcohol abuse
Yes 22 91 67 47 35 NA 0.029
N o 2 2 1 9 6 8 46 85 34 7
Heart failure†† 0.047BMC Infectious Diseases 2008, 8:49 http://www.biomedcentral.com/1471-2334/8/49
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when contracting the disease. There were significant dif-
ferences in the long-term cardiac mortality between vari-
ous causative agents of IE, the mortality being highest for
Enterococcus faecalis, as well as between various predispos-
ing cardiac conditions, the mortality being highest for
acquired valvular disease. The long-term cardiac mortality
was significantly lower for the patients who underwent
early surgery than for those who did not. Mortality was
significantly lower for the patients who were treated both
surgically and conservatively within 3 months than for
those who were treated only conservatively. The long-term
cardiac mortality was significantly higher for the patients
with serum creatinine value ≥ 100 μmol/l on admission
than for those with lower serum creatinine values. The
long-term cardiac mortality was significantly lower for the
patients who had a major criterion or vegetation on
echocardiography than for those who had no such find-
ings on echocardiography.
In age and sex adjusted multivariate analysis, heart failure
during 3 months of admission was significantly associ-
ated with high long-term cardiac mortality rates (HR 1.99,
95% CI 1.06 to 3.73; p = 0.032), whereas the presence of
a vegetation of echocardiography was significantly associ-
ated with low long-term cardiac mortality rates (HR 0.40,
95% CI 0.21 to 0.76; p = 0.005). When recurrent episodes
were excluded from the analyses, patients with heart fail-
ure had higher cardiac mortality rates, but the association
did not reach statistical significance (HR 1.81, 95% CI
0.95 to 3.44; p = 0.070). Yet, vegetation remained as a fac-
tor significantly associated with lower cardiac mortality
rates (HR 0.44, 95% CI 0.23 to 0.84; p = 0.012).
Yes 108 93 75 55 46 44
N o 1 3 5 9 8 8 97 55 54 6
Neurological complications††
Y e s 6 0 9 5 7 86 65 25 2 0 . 7 6 6
N o 1 8 3 9 6 8 46 55 04 3
Peripheral emboli††
Y e s 6 9 9 7 8 36 05 05 0 0 . 5 7 0
N o 1 7 4 9 5 8 26 75 14 3
Early surgery (in-hospital)
Y e s 6 7 9 9 8 98 27 67 3 <  0 . 0 0 1
N o 1 7 6 9 4 8 05 94 13 4
Mode of treatment††
Surgical 72 99 90 82 74 70 < 0.001
Conservative 171 94 79 59 41 33
Indications for in-hospital 
surgery
Congestive heart failure 35 97 85 72 61 55 0.002*
Valvular regurgitation without 
heart failure
18 100 94 94 94 94
Dehiscence of prosthetic valve 
without heart failure
8 100 88 88 88 88
Repeated emboli 3 100 100 100 100 100
Intractable infection 3 100 100 100 100 100
Erythrocyte sedimentation‡,§
≥ 5 0  m m / h 7 5 9 3 7 65 54 03 4 0 . 0 1 8
< 50 mm/h 74 97 89 77 56 53
White blood cell count‡,§S
≥ 10 × 109/ l 1 1 9 9 7 8 36 34 14 1 0 . 1 4 2
< 10 × 109/l 98 94 82 67 61 53
Serum C-reactive protein‡,¶
≥ 1 0 0  m g / l 1 0 0 9 6 8 36 24 84 8 0 . 9 2 7
< 100 mg/l 105 94 80 68 51 43
Serum creatinine value‡¶¶ < 0.001
≥ 100 μm o l / l 7 6 9 5 7 75 32 71 4
< 100 μm o l / l 1 4 2 9 7 8 77 16 15 9
*p values for overall group differences; †NA = non-applicable, the follow-up did not reach the time point for any patient of the group; ††within 3 
months of admission; ‡on admission; §data available for 149 episodes; §Sdata available for 217 episodes; ¶data available for 205 episodes; ¶¶ data 
available for 218 episodes
Table 1: Association between characteristics of infective endocarditis (IE) and survival (global and in different subgroups) at 2, 5, 10, 
15, and 20 years after the admission in 243 episodes of IE in 226 patients who survived over 1 year after the initial episode of IE BMC Infectious Diseases 2008, 8:49 http://www.biomedcentral.com/1471-2334/8/49
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Table 2: Association between characteristics of infective endocarditis (IE) and cardiac mortality at 2, 5, 10, 15, and 20 years after the 
admission in 243 episodes of IE in 226 patients who survived over 1 year after the initial episode of IE
Number of IE episodes in patients 
surviving 1 year
Survival (%) at different points of follow-up p value
2 years 5 years 10 years 15 years 20 years
Cardiac mortality 243 3 10 16 25 29
Gender
M a l e 1 7 4 291 52 63 1 0 . 8 0 1
F e m a l e 6 9 6 1 12 02 42 4
Age
18–64 years 172 1 5 11 22 26 0.002
≥ 6 5  y e a r s 7 1 1 0 2 13 23 23 2
Affected valves
Aortic 85 4 9 18 24 29 0.416*
Mitral valve 77 4 9 20 34 34
Tricuspid valve 12 0 0 0 NA NA
Two native valves 17 0 0 0 17 17
Prosthetic valve(s) 52 4 17 17 24 29
Causative agents of IE
Staphylococcus aureus 5 3 2 4444 0 . 0 3 2 *
Coagulase-negative staphylococci 22 10 20 30 30 30
Viridans streptococci 50 2 2 9 34 40
Enterococcus faecalis 18 17 17 25 63 63
Streptococcus pneumoniae 5 0 0000
O t h e r 2 2 001 61 62 8
Negative 73 1 17 22 25 25
Predisposing cardiac condition
Acquired valvular disease 49 8 19 29 41 41 0.015*
Prosthetic valves 55 4 16 16 23 28
B i c u s p i d  a o r t i c  v a l v e 2 6 0 0000
Mitral valve prolapse 30 3 3 15 29 29
Congenital heart disease 8 0 0 38 38 NA
No underlying cardiac condition 75 1 6 12 27 27
Echocardiogarphic findings
Major criteria
Yes 158 3 7 14 22 25 0.013
N o 8 5 4 1 52 23 23 6
Vegetation 0.007
Yes 139 4 6 12 22 22
No 104 3 15 22 30 36
Underlying conditions
Diabetes
Yes 21 5 5 5 29 29 0.325
No 222 3 10 18 26 30
Dialysis 0.340
Yes 5 25 25 NA NA NA
N o 2 3 8 391 62 52 9
Collagen disease 0.160
Yes 14 7 24 49 49 49
N o 2 2 9 391 52 42 8
Malignancy
Yes 11 10 10 40 NA NA 0.383
No 232 3 10 16 25 28
Intravenous drug use
Y e s 1 9 0 0N AN AN A 0 . 1 6 4
No 224 4 10 17 26 30
Alcohol abuse
Yes 22 9 15 15 25 NA 0.660
N o 2 2 1 391 62 52 9
Heart failure††BMC Infectious Diseases 2008, 8:49 http://www.biomedcentral.com/1471-2334/8/49
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Late valve surgery
Of all 326 episodes of IE in 303 patients treated between
1980 and 2004, valve surgery during the follow-up was
performed in 126. Fifteen patients underwent 2 valve
operations and 1 patient 3 valve operations. In 17
patients, the first valve operation was performed > 1 year
after the initial admission. Eight of them were operated on
between 1 and 2 years, 5 patients between 2 and 5 years,
3 patients between 5 and 9 years, and 1 patient 16 years
after the index episode of IE. In addition, 3 patients under-
going the first valve surgery during the initial hospitalisa-
tion underwent a reoperation more than 1 year (range 4
to 7 years) later. Thus, altogether 20 patients underwent
late valve surgery. The indications for late valve surgery
were: valvular regurgitation without heart failure (n = 15),
dehiscence of prosthetic valve (n = 3), valvular stenosis (n
= 1), and heart failure (n = 1).
Patients who underwent late valve surgery had signifi-
cantly lower overall mortality rates than those who did
not (HR 0.36, 95% CI 0.15 to 0.90; p = 0.029), but the car-
diac mortality rates were not significantly different (HR
0.50, 95% CI 0.15 to 1.62; p = 0.247).
Based on univariate analyses, patients with neurological
complications within 3 months of admission required
late valve surgery significantly less common than those
with no neurological complications (p= 0.032). In age
and sex adjusted multivariate analysis, no clinical factor
during the initial hospitalisation was associated with the
requirement of late valve surgery.
Patients with recurrences did not require late valve surgery
more commonly that those with no recurrences (HR 1.04,
95% CI 0.24 to 4.63; p = 0.955).
Y e s 1 0 8 6 1 52 32 83 1 0 . 1 1 0
N o 1 3 5 251 12 32 7
Neurological complications††
Yes 60 3 11 18 27 27 0.930
N o 1 8 3 391 62 53 0
Peripheral emboli†† 0.175
Y e s 6 9 381 42 02 0
No 174 3 10 17 27 32
Early surgery (in-hospital)
Yes 67 0 5 7 14 18 0.029
No 176 5 12 20 30 34
Mode of treatment†† 0.026
S u r g i c a l 7 2 04 91 51 9
Conservative 171 5 12 20 30 34
Indications for in-hospital 
surgery
Congestive heart failure 35 0 3 7 22 29 0.269*
Valvular regurgitation without 
heart failure
1 8 0 6666
Dehiscence of prosthetic valve 
without heart failure
8 0 13 13 13 13
R e p e a t e d  e m b o l i 3 0 0000
I n t r a c t a b l e  i n f e c t i o n 3 0 0000
Erythrocyte sedimentation‡,§
≥ 50 mm/h 75 4 14 23 29 33 0.527
< 50 mm/h 74 1 6 13 30 34
White blood cell count‡,§S
≥ 10 × 109/l 119 3 10 17 30 30 0.781
< 10 × 109/l 98 4 9 17 24 31
Serum C-reactive protein‡,¶
≥ 1 0 0  m g / l 1 0 0 371 01 31 3 0 . 0 8 0
< 100 mg/l 105 4 12 16 28 39
Serum creatinine value‡,¶P
≥ 100 μmol/l 76 5 12 24 42 60 0.001
< 100 μm o l / l 1 4 2 171 31 81 8
*p values for overall group differences; †NA = non-applicable, the follow-up did not reach the time point for any patient of the group; ††within 3 
months of admission; ‡on admission; §data available for 149 episodes; §Sdata available for 217 episodes; ¶data available for 205 episodes; ¶¶ data 
available for 218 episodes
Table 2: Association between characteristics of infective endocarditis (IE) and cardiac mortality at 2, 5, 10, 15, and 20 years after the 
admission in 243 episodes of IE in 226 patients who survived over 1 year after the initial episode of IE (Continued)BMC Infectious Diseases 2008, 8:49 http://www.biomedcentral.com/1471-2334/8/49
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Survival free of complications
Among the 1-year survivors, survival free of complications
(death, valve replacement, recurrence) after an episode of
IE is shown in Figure 3.
Repeated episodes of IE
Of all 303 patients treated between 1980 and 2004, 20
had more than 1 episode of IE including 17 patients with
1 recurrence of IE, 2 patients with 2 recurrences of IE, and
1 patient with 1 recurrence and 1 relapse of IE. The relapse
was a PVE caused by a Staphylococcus aureus strain genotyp-
ically identical with the strain causing native valve IE in
the same patient 3 months earlier. Of the 23 repeated epi-
sodes of IE, prosthetic valves were involved in 16.
1-year survivors
A total of 16 recurrences occurred among the 1-year survi-
vors. In univariate analysis, the only factor during the
index episode of IE significantly associated with recur-
rences in these patients was chronic dialysis (p < 0.001).
This association remained significant also in multivariate
analysis (HR 20.73, 95% CI 4.08 to 105.40; p < 0.001).
Patients with recurrent episodes of IE had significantly
lower overall mortality rates than those with no recur-
rences (HR 0.09, 95% CI 0.01 to 0.64; p = 0.017).
All patients
In univariate analysis, the factors during the index episode
of IE significantly associated with recurrences in all 303
patients with 23 recurrences were age < 65 years (p =
0.016) and diabetes (p = 0.022), chronic dialysis (p =
0.002) or IVDU (p < 0.001) as underlying conditions.
Also in age and sex adjusted multivariate analysis, chronic
dialysis (HR 12.56, 95% CI 2.54. to 62.24; p = 0.002),
IVDU (HR 5.49, 95% CI 1.84 to 16.43; p = 0.002) and dia-
betes (HR 3.71, 95% CI 1.30 to 10.62; p = 0.015)
remained significant. Patients with recurrent episodes of
IE had significantly lower overall mortality rates than
those with no recurrences (HR 0.05, 95% CI 0.01 to 0.33;
p = 0.002).
Discussion
In this study, we analysed the long-term outcome of the
patients treated for IE in a Finnish teaching hospital dur-
Kaplan-Meier curves of the overall mortality and cardiac mortality for 243 episodes of infective endocarditis in 226 patients,  who survived longer than 1 year after the initial episode. Figure 1
Kaplan-Meier curves of the overall mortality and cardiac mortality for 243 episodes of infective endocarditis in 
226 patients, who survived longer than 1 year after the initial episode. The numbers at different time points refer to 
the number of patients being followed up and at risk for event at the beginning of the time period. Zero on the time access 
indicates 1 year.BMC Infectious Diseases 2008, 8:49 http://www.biomedcentral.com/1471-2334/8/49
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Long-term outcome was analysed for 243 episodes of infective endocarditis in 226 patients, who survived longer than 1 year  after the initial episode. Figure 2
Long-term outcome was analysed for 243 episodes of infective endocarditis in 226 patients, who survived 
longer than 1 year after the initial episode. Kaplan-Meier curves of the overall survival for patients with and without 
heart failure during 3 months of admission (a), and for those undergoing and not undergoing early (in-hospital) surgery (b). The 
numbers at different time points refer to the number of patients being followed up and at risk for event at the beginning of the 
following time period. Zero on the time access indicates 1 year.
a
b BMC Infectious Diseases 2008, 8:49 http://www.biomedcentral.com/1471-2334/8/49
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ing a period of 25 years. Among the 1-year survivors, the
overall survival was 66% at 10 years, 51% at 15 years and
45% at 20 years. These figures are comparable with the
results of previous studies [12,15], although we are not
aware of any earlier study in which the long-term survival
has been analysed in an identical manner. Collectively,
these data illustrate that despite major diagnostic and
therapeutic advances, the mortality associated with IE
remains high. At 10 years of follow-up, as many 51% of
our whole patient population and 34% of the 1-year sur-
vivors had died. Admittedly, a few studies have been pub-
lished reporting somewhat higher survival rates [13].
One of the main purposes of the present study was to
define which clinical characteristics or complications of IE
during the initial phase of endocarditis would be associ-
ated with an adverse long-term outcome of the patients.
Consistent with previous studies [12,14], older age at the
time of contracting the disease predicted an adverse long-
term outcome. Chronic dialysis as an underlying condi-
tion predicted a poor overall long-term prognosis, as did
alcohol abuse and collagen disease. In the patients with
collagen disease, the severe nature of the underlying dis-
ease may have contributed to high mortality. Of all 9
patients with collagen disease who died during the fol-
low-up, 3 needed chronic dialysis, 1 had nephrotic syn-
drome and in 3 patients, the cause of death was a
malignancy. On the other hand, the survival was signifi-
cantly better for the patients with IVDU than for those
with no IVDU, but all of the patients with IVDU were
young and most of them had a tricuspid valve disease with
no mortality. Moreover, the follow-up time of these
patients was short, since the first IVDU-associated case of
IE occurred in our hospital in 1996.
Among the complications of IE, heart failure during the
first 3 months of admission was significantly associated
with long-term overall mortality and cardiac mortality.
This corroborates other studies, which have found that
heart failure is a major risk factor for long-term mortality
Kaplan-Meier curves of survival free of recurrent endocarditis, valve replacement, and death after an episode of infective endo- carditis. Figure 3
Kaplan-Meier curves of survival free of recurrent endocarditis, valve replacement, and death after an episode 
of infective endocarditis. The numbers at different time points refer to the number of patients being followed up and at risk 
for event at the beginning of the following time period. Zero on the time access indicates 1 year.BMC Infectious Diseases 2008, 8:49 http://www.biomedcentral.com/1471-2334/8/49
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[15]. Also among the surgically treated patients, the over-
all survival was lowest for those who were operated on for
heart failure, underscoring the importance of heart failure
as a poor long-term prognostic sign.
Neurological manifestations and peripheral emboli usu-
ally develop early in the course of endocarditis [16,22-24].
We have previously shown that in this patient population,
the occurrence of neurological complications or periph-
eral emboli was significantly associated with short-term
mortality as well as with mortality for up to 1 year of the
admission [16]. In contrast, the results of the present
study show that the long-term survival was practically
similar for the patients with or without neurological man-
ifestations or peripheral emboli during the acute phase of
their illness (Table 1). This finding is not surprising, since
once the patient has solved such an acute complication, it
seems logical that it no longer influences the long-term
prognosis.
In our series, early surgery was performed in 27.3% (89)
of all 326 episodes [16]. Evaluation of the role of cardiac
surgery on the prognosis of the patients with IE is a com-
plex issue. Although early surgery is evidently life saving
for certain groups of patients, it does not necessarily
decrease the total mortality, since more and more criti-
cally ill patients are being treated surgically. This may be
one of the reasons why the results regarding the role of
early surgery as a prognostic factor have been conflicting.
For example, when studying 280 patients treated in their
unit between 1970 and 1982, Malquarty et al. [25] did not
find any significant difference in the survival rate at 5
years between the surgical and non-surgical treatment
groups. Neither did Tornos et al. [8] find any association
between early surgery and a better survival rate during a
15-year follow-up among 140 patients hospitalised
between 1975 and 1990. On the other hand, according to
Bishara et al. [26], early surgical intenvention compared
with medical therapy alone was associated with increased
long-term survival rates in patients with IE treated
between 1987 though 1996, primarily when IE was
caused by S. aureus. Similarly, long-term survival was pre-
dicted by early surgical treatment in 212 patients with IE
treated between 1980 and 1995 in a series described by
Netzer at al. [15]. Moreover, Castillo et al. [13] have
reported that a high early surgery rate was related to good
long-term results in 138 cases of IE hospitalised between
1987 and 1997. Our results corroborate these findings:
early surgery led to significantly lower overall and cardiac
mortality rates in these 1-year survivors, although in mul-
tivariate analysis, the association was not significant
regarding the long-term cardiac mortality. Thus, the
results of the present study support the contention that a
successful and correctly focused early valve surgery may
decrease mortality due to IE. This could be accomplished
by a careful selection of appropriate patients to be treated
surgically.
The prognosis of the patients surviving the initial phase of
endocarditis is considered to be due to 3 main factors: the
development of heart failure, the risk of recurrences and
the need for later valve replacement. In our patients,
repeated episodes of IE were not common, as 20 (6.6%)
of all 303 patients had recurrences and only 1 patient
(0.3%) had a relapse. The rate of recurrences concurs with
other published series, in which the rate of recurrences has
varied between 3.9 and 16% [12,14,27-29], but the rate of
relapses was here somewhat lower than the 1.1 to 3.3%
relapse rate reported in earlier studies [8,14,30]. Chronic
dialysis, diabetes and IVDU were shown to be risk factors
for the development of recurrences when analysed for all
303 patients treated in our hospital between 1980 and
2004. IVDU has been shown to be a risk factor also in
some other [29], but not all [14], previous studies.
Although recurrent endocarditis is considered to be a risk
factor for death [14], the development of a recurrent epi-
sode of IE did not confer a poor prognosis in our patients;
in direct contrast, patients with recurrences had a better
long-term overall outcome than those with no recur-
rences. At least a partial explanation for this could be that
IVDU was a risk factor for the recurrences of IE. The
patients with IVDU had a significantly lower mortality
than those with no drug use, evidently due to the fact that
they commonly had tricuspid valve IE with low mortality.
Late surgery was required in 17 (7.0%) of the 243 epi-
sodes. None of the clinical parameters during the initial
episode of IE were found to be associated with the require-
ment for late valve surgery. The requirement for late sur-
gery was not increased even in the patients with recurrent
episodes of IE. Also this could be partly explained by the
positive association between the development of recur-
rences and IVDU.
Survival free of complications decreased with time.
Although the estimate for 20-year survival was 45%, the
estimate for 20-year survival free of complications, i.e.
recurrent endocarditis or valve replacement, was only a lit-
tle more than 30%.
Conclusion
In our patients, heart failure within 3 months of the
admission for the index episode of IE was the complica-
tion, which significantly predicted a poor long-term out-
come. Patients who underwent surgery during the initial
hospitalisation for IE faired significantly better than those
who did not. Corroborating earlier findings, these results
support the contention that a successful and correctly
focused early valve surgery may decrease mortality due to
IE. This could be accomplished by a careful selection ofBMC Infectious Diseases 2008, 8:49 http://www.biomedcentral.com/1471-2334/8/49
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appropriate patients to be treated surgically. It must be
admitted that the heterogeneity of the patient population
included in this study may be one limitation when apply-
ing our results in the daily clinical practice. An analysis of
long-term prognostic factors in some defined subgroups
of our whole study population may provide further valu-
able information in the future.
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